PRKCA and lung carcinoma: The results indicated that pre‐treatment with PLCβ, PKCα and c‐Src inhibitors (U73122, GF109203X and PP2) reversed CXCL13‐promoted cell migration and VCAM‐1 in lung cancer cells (Figure 5A,B).